Citalopram Did Not Significantly Improve Anxiety in Children with ASD Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors

Objective: Anxiety disorders are amongst the most common co-occurring conditions in autism spectrum disorder (ASD). Despite their prevalence and impact, there are no randomized controlled trials (RCTs) aimed at evaluating the efficacy of selective serotonin reuptake inhibitors (SSRIs) for anxiolysis in this population, who may have a different biological basis for anxiety.

Method: Secondary analyses of the STAART double-blind, placebo-controlled RCT of citalopram in children with ASD examined whether citalopram reduced anxiety measured on the parent-reported Child and Adolescent Symptom Inventory (CASI-4) as the primary outcome. An
intention to treat analysis involving all 149 participants used multiple imputation for missing data and included baseline stratification factors of age group and site, amongst others. We pre-specified as clinically significant a 33% reduction in anxiety in citalopram versus placebo, coinciding with 80% power. We tested whether communicative ability on the Vineland Communication score moderated treatment effect and explored whether initial anxiety was associated with greater adverse events, which could impact on dose titration and achieving optimal dose. 

Results: Both groups showed substantial reduction in anxiety. Citalopram was associated with a non-significant 16.5% greater reduction (observed coefficient = -.181, bootstrap SE = .126, p = .151, CI =-.428, .066). Anxiety reports were significantly lower in children with reduced communicative ability, but communicative ability did not moderate the treatment effect (interaction p=.294). Initial anxiety levels were not associated with increased adverse effects (interaction ps .162 to .954). 

Conclusion: Citalopram did not statistically significantly improve anxiety in children with ASD. Clinicians should be cautious in their use of SSRIs for this indication. There remains a need for well-powered clinical trials testing the efficacy of SSRIs amongst autistic children with anxiety disorders.
Disclosures

Drs. Simonoff and Pickles currently receive support from the National Institute of Health Research (NIHR) Biomedical Research Centre at South London and Maudsley Foundation Trust (IS-BRC-1215-20018), the NIHR through a programme grant (RP-PG-1211-20016) and Senior Investigator Awards (NF-SI-0514-10073 and NF-SI-0617-10120), the European Union Innovative Medicines Initiative (EU-IMI 115300), Autistica (7237)m Medical Research Council (MR/R000832/1, MR/P019293/1), the Economic and Social Research Council (ESRC 003041/1) and Guy’s and St Thomas’ Charitable Foundation (GSTT EF1150502) and the Maudsley Charity. Dr. King receives support from the University of California San Francisco.

Dr. Hollander receives support from the Department of Defense Autism Research Program (AR160104), Orphan Products Division of Food and Drug Administration (FD-R-05106), and Roche Pharmaceuticals and GW Pharma. Dr. Sikich currently receives support from Duke University, the US National Institutes of Health (P50HD093074-03) and (HHSN275201000003I TO), and Roche Pharmaceuticals and Boehringer-Engelheim to conduct Industry Sponsored Trials.

Acknowledgements:

This re-analysis was funded by NIHR NF-SI-0617-10120 and Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Citalopram Did Not Significantly Improve Anxiety in Children with ASD Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors

Emily Simonoff MD
Florence Mowlem PhD
Oliver Pearson
Evdokia Anagnostou, MD
Craig Donnelly MD
Eric Hollander MD
Bryan H. King MD
James T. McCracken MD
Lawrence Scahill PhD
Linmarie Sikich MD
Andrew Pickles PhD

1 Department of Child & Adolescent Psychiatry, King’s College London, Institute of Psychiatry, Psychology & Neuroscience and Maudsley Biomedical Research Centre for Mental Health, London UK
2 Department of Biostatistics and Health Informatics, King’s College London, Institute of Psychiatry, Psychology & Neuroscience and Maudsley Biomedical Research Centre for Mental Health, London UK
3 Holland Bloorview Kids Rehabilitation Hospital
4 Department of Pediatrics, University of Toronto, CA
5 Dartmouth-Hitchcock Medical Center, Lebanon, USA
6 Autism and Obsessive Compulsive Spectrum Program, Psychiatric Research Institute of
7 Montefiore Einstein, Albert Einstein College of Medicine, Bronx, NY, USA
8 University of California San Francisco, Department of Psychiatry, Weill Institute for
9 Neurosciences, San Francisco, CA, USA
10 Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at
11 UCLA, Los Angeles, CA, US
12 Department of Pediatrics, Emory University School of Medicine, Marcus Autism Center,
13 Atlanta, GA, USA
14 Duke Center for Autism and Brain Development, Department of Psychiatry, Duke University
15 School of Medicine, Durham, NC, USA
16 Corresponding author: Emily Simonoff Email: emily.simonoff@kcl.ac.uk
17 Word count total (excluding abstract and references): 3993
18 Tables: 2
19 Figures: 3
20 Supplementary tables: 2
21 Running head: Citalopram for anxiety in ASD
Abstract

Objective: Anxiety disorders are amongst the most common co-occurring conditions in autism spectrum disorder (ASD). Despite their prevalence and impact, there are no randomized controlled trials (RCTs) aimed at evaluating the efficacy of selective serotonin reuptake inhibitors (SSRIs) for anxiolysis in this population, who may have a different biological basis for anxiety.

Method: Secondary analyses of the STAART double-blind, placebo-controlled RCT of citalopram in children with ASD examined whether citalopram reduced anxiety measured on the parent-reported Child and Adolescent Symptom Inventory (CASI-4) as the primary outcome. An intention to treat analysis involving all 149 participants used multiple imputation for missing data and included baseline stratification factors of age group and site, amongst others. We pre-specified as clinically significant a 33% reduction in anxiety in citalopram versus placebo, coinciding with 80% power. We tested whether communicative ability on the Vineland Communication score moderated treatment effect and explored whether initial anxiety was associated with greater adverse events, which could impact on dose titration and achieving optimal dose.

Results: Both groups showed substantial reduction in anxiety. Citalopram was associated with a non-significant 16.5% greater reduction (observed coefficient = -.181, bootstrap SE = .126, p = .151, CI = -.428, .066). Anxiety reports were significantly lower in children with reduced communicative ability, but communicative ability did not moderate the treatment effect.
(interaction $p = .294$). Initial anxiety levels were not associated with increased adverse effects (interaction $ps .162$ to .954).

Conclusion: Citalopram did not statistically significantly improve anxiety in children with ASD. Clinicians should be cautious in their use of SSRIs for this indication. There remains a need for well-powered clinical trials testing the efficacy of SSRIs amongst autistic children with anxiety disorders.
Keywords: autism, autistic disorder, randomized controlled trial, selective serotonin reuptake inhibitors, anxiety
Introduction

Autism spectrum disorder (ASD) is a heterogeneous condition characterized by impairments in social communication, restricted, repetitive behaviors and interests and sensory abnormalities. ASD begins early in development and typically has lifelong impact on a range of domains including socialization, cognition, adaptive function, and physical and mental health (Lord et al. 2020). Anxiety disorders are one of the two most common co-occurring conditions in autism (Simonoff et al. 2008; Lai et al. 2019). Indeed, anxiety was highlighted in Kanner’s first description of autism as a disorder of affective control (Kanner 1943). Prevalence estimates of anxiety vary but converge around 40-50%, with a substantial additional proportion exhibiting sub-diagnostic symptoms (Kent and Simonoff 2017). Anxiety symptoms and disorders in people with ASD can be present from the preschool period (Gadow et al. 2004; Salazar et al. 2015), remain common across the lifespan (Lever and Geurts 2016) and appear to be stable over time (Simonoff et al. 2013; Stringer et al. 2020). There is considerable inconsistency about whether the prevalence of anxiety disorders varies according to the presence of intellectual disability (ID) (Kent and Simonoff 2017) with methodological concerns that anxiety may be particularly under-recognized and under-reported in those with low levels of verbal ability (Salazar et al. 2015; Gadow et al. 2004; Hallett et al. 2013; Sukhodolsky et al. 2008). Anxiety can cause high levels of distress and autistic people and their parents/caregivers have ranked the study of anxiety and its interventions as one of the most important research areas (Wallace et al. 2014).

In non-autistic individuals, there is an established evidence base demonstrating benefits of pharmacological interventions for anxiety disorders in non-autistic children (Walkup et al. 2004).
2008) and adults (Baldwin et al. 2011). However, to date, no randomized controlled trials (RCTs) have focused on their use in children with ASD and co-occurring anxiety. There are important biological and psychological differences in the ASD population that may alter the efficacy and safety of using SSRIs in this patient group. About one-quarter of people with ASD have hyperserotonemia (Gabriele et al. 2014) but the role of this variability on SSRI treatment response is not well understood. More generally, patients with ASD may be more susceptible to adverse effects related to pharmacological treatments, as shown for methylphenidate (Research Units on Pediatric Psychopharmacology Autism Network 2005; Simonoff et al. 2013).

Due to the impairments in communication, interoception and emotional literacy, it may be more difficult to ascertain both internally experienced treatment response and adverse effects in people with ASD.

There are also cautions about SSRIs in younger people. In the non-autistic population, younger people (Strawn et al. 2014) and children compared to adolescents are more sensitive to treatment-emergent adverse effects, particularly behavioral activation (Safer and Zito 2006). Although current guidelines do not recommend the use of SSRIs in the routine treatment for anxiety in ASD (National Collaborating Centre for Mental Health 2013; Howes et al. 2017; Vasa et al. 2014; Williams et al. 2013), in the US and UK SSRIs account for at least 10-20% of psychiatric prescriptions for youth and 20-50% in adults with ASD (Aman et al. 2005; Hsia et al. 2014; Oswald and Sonenklar 2007; Houghton et al. 2017).

To explore the efficacy and adverse effects of SSRIs in treating anxiety in people with ASD, we make use of previously collected data from an RCT of citalopram in children with ASD, aimed at evaluating its efficacy in reducing core symptoms of repetitive and stereotyped
behavior (King et al. 2009). We capitalize on the blinded parent-reported measures of anxiety collected pre-randomization and at 12 weeks to examine the effects of citalopram compared to placebo.

Method

Study Design

A detailed description of the STAART citalopram trial has been published previously (King et al. 2009). The clinical trial (identifier: NCT00086645) was registered at www.clinicaltrials.gov prior to initiation. This multi-center randomized double-blind, placebo-controlled parallel arm trial aimed to assess the efficacy and safety of citalopram for the core symptoms of repetitive behaviors in children with ASD. Participants were randomized using permuted blocks with randomly varying block sizes stratified by site (6) and age (5-11 years versus 12-17 years). The mean (SD) dosages of citalopram and placebo at week 12 were 16.5 (6.5) mg (mode, 20 mg) and 18.5 (3.5) mg (mode, 20 mg), respectively \((p=.05)\). Parent-reported adherence to treatment was high in both groups (mean [SD], 96.1% [7.8%] for the citalopram-treated group and 98.6% [3.1%] for the placebo group; \(p=.03\)). The primary analyses found no significant difference in response on the Clinical Global Impression–Improvement (CGI-I) scale between the citalopram (32.9% response rate) and placebo group (34.2% response rate) (King et al. 2009). However, compared with placebo, the citalopram group was significantly more likely to exhibit adverse events (97.3% reported at least 1 treatment-emergent adverse event) than the placebo group (86.8%, \(p = .03\)).
For the present secondary analyses, the aim was to determine whether citalopram reduced levels of parent-reported anxiety symptoms in comparison with placebo and whether anxiety response was moderated by adverse effects.

Subjects

A total of 149 children (128 males) aged between 5 and 17 years ($M = 9.4$ years, $SD = 3.1$ years) who (i) met DSM-IV-TR criteria for autistic disorder, Asperger disorder or pervasive developmental disorder, not otherwise specified (determined by an experienced clinician and informed by the Autism Diagnostic Interview–Revised [ADI-R (Lord et al. 1994)] and the Autism Diagnostic Observation Schedule [ADOS (Lord et al. 2000)]), (ii) had an illness severity rating of at least moderate on the Clinical Global Impressions – Severity (CGI-S) of Illness Scale (Guy 1976), and (iii) at least moderate on compulsive behaviors ($\geq 8$ on the sum of items 1A, 2, 3, and 5) scores measured with the Children’s Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders (CYBOCS-PDD) (Scahill et al. 2006). Exclusion criteria can be found in the primary paper (King et al. 2009) and at www.clinicaltrials.gov (identifier: NCT00086645).

Each of the six participating sites received ethical approval from their institutional review board (IRB) and informed consent was obtained from all study participants and/or legal representatives prior to data collection. An external board convened by the National Institute of Mental Health monitored the trial. No additional approval was sought for these secondary analyses.

Study assessments
Primary outcome. The primary outcome measure for the current analysis was parent-reported anxiety at 12 weeks post-randomization, based on a total score for 20 items from the Child and Adolescent Symptom Inventory-4 (CASI-4; Gadow and Sprafkin 2002). Items are scored from 0 – 3 (0=Never; 1=Sometimes, 2=Often, 3=Very Often), allowing a potential score range of 0-60. These items were used in a previous studies of the parent-reported anxiety in children with ASD (Sukhodolsky et al. 2008; Hallett et al. 2013) and include domains of generalized anxiety disorder, simple phobia, social phobia and separation anxiety disorder, but not obsessive-compulsive disorder or post-traumatic stress disorder, in line with the inclusion of disorders in pharmacological studies in typically developing anxious children (Research Units on Pediatric Psychopharmacology 2001; Walkup et al. 2008). Furthermore, the OCD symptoms have potential overlap with restricted and repetitive behaviors, for which no treatment effect was identified in the primary analysis. For the present analysis, as participants had not been selected to have high anxiety levels, we looked for a treatment-related decrease in symptoms that was proportional to each participant’s level at baseline (thus no reduction being expected for those without symptoms) with a positive clinical response defined as a 33% decrease in the total anxiety score at week 12 post-randomization.

For exploratory analyses, we also defined a subgroup of participants whose questionnaire scores were above the pre-determined threshold for a likely anxiety disorder in at least one of the above categories (Gadow and Sprafkin 1997).

Adverse events. Treatment-emergent adverse events were elicited at each biweekly visit using the Safety Monitoring Uniform Report Form completed by the clinician with the parent and on examination (Greenhill et al. 2004). We grouped the individual adverse events into
three categories in line with their original description: neuropsychiatric adverse events
(increased energy level, disinhibited or impulsive behavior, decreased attention, hyperactivity,
and stereotypy), insomnia-related adverse events (any insomnia, initial, midcycle or terminal),
and non-CNS adverse events (diarrhea, vomiting or nausea, and dry skin or pruritus).

*Additional included measures.* The additional measures were used to improve efficiency,
reduce bias associated with missing data, and to examine potential masking of treatment effect
arising from the difficulty of reporting on anxiety symptoms of children with poor
communication. These measures were the parent-reported Vineland Adaptive Behavior Scale
(VABS) communication scale age equivalent, the ADOS module (which is selected based on
spoken language competence), chronological age and non-verbal IQ, measured variously on the
Leiter-Revised, Wechsler Intelligence Scale for Children-IV, Wechsler Abbreviated Scale of
Intelligence, Mullen Scales of Early Development, and Stanford-Binet Test. The severity of
repetitive and stereotyped behavior, measured on the CGI-S, was weighted to consider
repetitive behaviors, as well as the CGI-I score at 12 weeks. As behavioral disturbance has also
been associated with parent reports of anxiety symptoms (Sukhodolsky et al. 2008) and could
affect parents’ ability to identify anxiety, the baseline irritability subscale of the parent-
reported Aberrant Behavior Checklist (ABC) (Aman and Singh 1985) was added. Body Mass
Index (BMI), in conjunction with age, accounts for baseline weight differences which could be
related to therapeutic drug levels.

*Statistical Analysis*

Drawn up by AP, FM and ES who were not involved in the original trial and without
knowledge of participants’ treatment assignment, the Statistical Analysis Plan was pre-
registered on The Open Science Framework (https://osf.io/h67ek/). In summary, analyses used the intention-to-treat (ITT) population (to test between-group (placebo versus citalopram) change from baseline in the primary outcome of anxiety at the post-intervention 12-week assessment. Analysis used the log-transformed anxiety scores (with 1 added to avoid log of zeros) as Gaussian variables and estimated the treatment effect on a log scale (i.e., as a multiplicative treatment effect on the total score). This means that treatment is expected to have more effect on those with more symptoms, less effect on those with fewer symptoms, and no effect on those with none. This method is particularly suitable where the outcome of interest has a wide range of values at baseline. This model is likely statistically more powerful than limiting the analysis to the high scorers only. As a post hoc sensitivity analysis (added after pre-registration of the analysis plan), we also fitted a model just to those participants whose questionnaire scores were above the pre-determined threshold for a likely anxiety disorder as described above. The models were estimated using a structural equation modelling (SEM) framework in which baseline and endpoint are allowed a non-zero covariance, and no treatment group difference is allowed for the response pre-randomization. While yielding the same estimates as ANCOVA when data are complete this method incorporates incomplete observations. Analyses were performed in Stata version 17.0 (StataCorp. 2021) using the sem command option, method(mlmv), which is consistent with ITT. Original stratification variables were included in the analysis model (age group and site). Residuals were checked using normal probability plots. Statistical tests and 95% confidence intervals were two-sided.

We then examined whether if the effect of citalopram on anxiety is moderated by communicative level, following our hypothesis that parents may find it more difficult to discern
their children’s anxiety when they cannot directly communicate these experiences. We used
the VABS Communication age equivalent score and report both the VABS main effect and the
group (citalopram versus placebo) by VABS interaction. Finally, exploratory analysis examined
whether initial levels of anxiety might be associated with higher levels of adverse events, which
could have interfered with achieving optimal dose for anxiety reduction. We examined whether
the three adverse events profiles were influenced by pre-randomization CASI-4 score and
whether this differed by group (group-by-baseline anxiety score interaction). This used Poisson
regression analysis conducted separately for each of the three adverse events categories,
adjusting for dose-by-weight.

 Missing data. We used single imputation of occasional missing items by chained
equations and predictive mean matching (White et al. 2011). The items were imputed in a
single model incorporating both baseline and outcome. Non-verbal IQ, VABS Communication
age equivalent, CGI-S at baseline as well as CGI-I at week 12, ABC irritability, BMI, sex, site,
treatment group and chronological age were included in the imputation model.

Total scores were then calculated using the complete and imputed item values for
participants with 6 or fewer missing items (30% or fewer items missing out of the 20 items). For
those with more than 30% of missing items, their total score was set to missing before the main
analysis, thus being treated as Missing-At-Random (MAR) within full maximum likelihood model
estimation.
Sensitivity Analysis. The main analysis was repeated with missing baseline and endpoint
data in the treatment group replaced by a 10% worsening of scores (i.e. 10% greater anxiety).
This provided a further test of the robustness of the primary analysis.

Power. Using the ITT sample of 149, power was calculated, subsequent to specifying the
level of clinically significant treatment effect, using an ANCOVA approach for two-tailed
alpha=.05, assuming a correlation of 0.5 between measurement time points. This gave 80%
power for an effect size of -0.4 on the log scale, equating to a 100(1-exp(-0.4)) ≃ 33% reduction
in anxiety in the citalopram group compared to placebo. Using the same calculation adjusting
for the number of complete cases specified in the primary paper (i.e., 13 cases missing in each
group), the power would be 73% to detect the same effect size.

Results

Efficacy

Table 1 shows the sample characteristics of the 149 participants. At baseline screening,
118 (citalopram n=60, placebo n=58) had complete data on all anxiety items, a further 19 had 6
or fewer missing items that were imputed, and 12 were left missing. Corresponding numbers
for the week 12 endpoint were 94 (citalopram n=49, placebo n=45), with 20 imputed and 35
left missing. The distribution of anxiety scores by group and time point are shown in Figure 1.

Table 1

Figure 1

There was a substantial decrease in parent-reported anxiety symptoms in both groups
over the course of the trial. The estimated baseline mean of 11.1 symptoms (CI 9.7 to 12.5) fell
by 32% in the placebo group to 7.5 (CI 6.0 to 8.9), and by 44% in the citalopram group to 4.7 (CI 2.6 to 6.8). The estimated effects are shown in Figure 2, using the log-scale on which the analysis was undertaken in the left panel. The simple additive treatment effect on this log-scale corresponded to a proportional/multiplicative effect on the raw total score scale. The placebo group experienced a substantial reduction in symptoms, falling almost exactly on the red-dashed line for 67% of baseline. The line for the citalopram group, while lower than placebo, does not achieve the additional 33% reduction we set as the minimum clinical requirement (solid red line). Model estimates found no significant difference in the reduction of anxiety symptoms from baseline to week 12 between the citalopram-treated and placebo group (observed coefficient = -.181, bootstrap SE = .126, p = .151, CI = -.428, .066). This corresponded to a 16.5% greater reduction in the citalopram group, less than the level of 33% between-groups difference pre-identified as clinically significant. However, this clinically significant threshold fell within the confidence interval of our estimate which spanned a relative reduction of 36.8% to an increase of 3.7% (1000 replicate bootstrap CI).

Figure 2

The questionnaire algorithm for likely disorder indicated 86 of the 149 (58%) children met threshold for at least one anxiety disorder (Figure 3). The model fitted to this subset estimated the initial symptom score of 16.5, declining by 40.2% (CI 31.8, 48.5) in the placebo group and 49.5% (CI 37.9, 61.4) in the citalopram group, corresponding to 15.6% greater reduction (CI -8.1, 38.3) in the citalopram group, very close to the whole sample estimate.

Figure 3
A sensitivity analysis, using total scores, where scores for those in the citalopram-treated group with more than 6 missing items for screener or outcome anxiety were replaced with a 10% worsening of their total anxiety score, produced similar results to the main analysis, with a 13.4% reduction in the citalopram group compared to placebo (observed coefficient = - .144, bootstrap SE = .099, p = .144).

**Moderation of treatment effect by communication level**

We identified a main effect of VABS communication level on anxiety score at week 12 (coefficient = .006, SE = .002, p = .018, 95% CI = .001, .010, supporting the idea that parent-reported anxiety symptoms are lower in children with reduced communication ability. However, the effect of citalopram on reducing anxiety from screen to week 12 was not moderated by communication level (group-by-communication level interaction: coefficient = -.003, SE = .003, p = .294, 95% CI = -.009, .003), indicating that the lower anxiety scores in low-functioning children does not mask a significant treatment effect.

**Adverse Events**

As detailed in the primary paper, adverse events were more likely to be exhibited in the citalopram-treated group. Table 2 describes the number of participants from the citalopram and placebo groups exhibiting at least one adverse event in each of the three domains. Poisson regression analysis, examining whether the adverse event score is influenced by baseline anxiety and if this differs by group (adjusting for final prescribed dose by weight: citalopram n=51, mean = 0.51, SD= 0.26; placebo n=51, mean = 0.54, SD = 0.24), did not show a significant group-by-baseline anxiety score interaction for any of the AE categories (neuropsychiatric:
coefficient = -.45, SE = .32, p = .162, 95% CI = -1.08, .18; insomnia: coefficient = -.40, SE = .34, p = .248, 95% CI = -1.07, .28; non-CNS: coefficient = -.02 , SE = .43, p = .954, 95% CI = -.87, .82).

Table 2

Discussion

Anxiety symptoms and disorders are one of the most common co-occurring conditions in children and adolescents with ASD and SSRIs are frequently prescribed, despite an absence of RCT-based evidence. Here, we tested for a treatment-specific reduction in parent-reported anxiety symptoms in youth receiving citalopram versus placebo using data from an RCT aimed at assessing the efficacy of citalopram for repetitive behaviors. We pre-defined a clinically meaningful effect size of -0.4, which for our log-transformed scores approximated a 33% reduction in symptoms compared to the placebo group. Both groups showed a reduction in CASI anxiety symptom scores across the 12-week trial, suggesting substantial placebo effect, regression to the mean or both. The observed greater improvement in the citalopram compared to placebo group of 16.9% was robust to missing data assumptions, and selection of participants for disorder, increasing confidence in the estimated group difference. This difference had wide confidence intervals but was not statistically significant and did not meet our threshold for clinical significance.

The previous literature on SSRIs in ASD using randomized and blinded designs is extremely limited. In a placebo-controlled crossover trial of fluoxetine in 45 children with ASD designed to examine effects on core symptoms and repetitive behaviors, there was a lower rate of treatment-emergent anxiety on active treatment versus placebo (Hollander et al. 2005).

Another tiny (N=6) placebo-controlled crossover RCT of fluoxetine in children reported
significant anxiety reduction on active medication (Buchsbaum et al. 2001). Other findings are limited due to open-label or case review designs. The case review literature may be over-optimistic in describing benefits of SSRI treatment because it does not account for placebo effects, which were of moderate magnitude in this study (Thorkelson et al. 2019).

We confirmed the finding from other studies using the CASI-4 (Sukhodolsky et al. 2008; Hallett et al. 2013) that parent-reported levels of anxiety symptoms are higher in children with greater communicative ability. However, the current analyses do not identify a stratification effect, or that the inclusion of lower communication ability children masked a treatment effect. Furthermore, the finding that initial anxiety scores neither predicted level of adverse events, nor showed an interaction with treatment group, provides some reassurance that achieving effective dosing was not limited by levels of anxiety.

Strengths of the current study include its moderately large sample size. The original study was well-conducted and described; it employed an ITT design with comparatively high levels of completion and careful medication dose adjustments. The present statistical analysis was pre-specified and lodged on Open Science Framework, except for the additional sensitivity analysis that was restricted to the participants with a likely anxiety disorder. The structural equation modeling and imputation provided efficient and unbiased estimates of ITT effects. The selection of anxiety items from the parent-reported CASI-4 is consistent with that used in other autism studies (Sukhodolsky et al. 2008) and has minimal if any overlap with repetitive behaviors examined in the primary paper.

An important limitation is that the original study was not designed to address the present question of efficacy of SSRIs for anxiety disorders. We therefore tested for a treatment
effect that was proportional to the initial severity of anxiety symptoms, avoiding the dilution effect of participants with little anxiety on treatment effect estimation. Our sensitivity analysis limited to those with symptom levels indicative of an anxiety disorder provided a similar point estimate, but with expected wider confidence intervals. The CASI-4 is not a diagnostic instrument and the use of questionnaire scores to identify a subgroup with likely disorder should be treated with caution. The present study did not include blinded clinician ratings of global improvement focusing on anxiety, currently the gold standard in many psychiatry studies. Furthermore, it is unclear whether the CASI-4 is the most sensitive measure of anxiety symptoms in children with ASD (Hallett et al. 2013).

Consistent with other research groups using the CASI-4, we found reduced levels of parental symptom reports in those with lower communication levels, which may reflect measurement insensitivity in children with significantly reduced communication. New measures focusing on observable behaviors may be more sensitive to non-verbal manifestations of anxiety (Scahill et al. 2019). In evaluating treatment effects in people with ASD and significant impairments in communication, an optimal measurement strategy would also include objective measures. Children with ASD and anxiety often have high levels of irritability and maladaptive behaviors and previous research has shown these characteristics are difficult for parents to distinguish on questionnaires (Mikita et al. 2015). Future consideration of measures and experimental paradigms that discriminate anxiety- and anger-mediated arousal will be important.

Finally, the criterion of a Cohen’s d effect size of 0.4 on the log-scale (corresponding to a 33% reduction) that we chose was in part in order that the analysis would have adequate
power for any possible positive finding to be reliable. However, Cohen’s d is scaled by baseline
standard deviation, and an effect size of 0.4 may correspond to a substantially greater change
where participants are not selected on baseline score (as here) than that found in the typical
purpose designed trial where participants are recruited to be uniformly high scorers. For
example, Wagner et al. (2004) report data for a similarly sized but purpose designed RCT for
non-ASD adolescents, all with high scores, corresponding to symptom reductions of ~28% for
placebo and ~38% for citalopram, effects a little smaller than those that we found (32% and
44%). However, with their more homogeneous participants, these effects gave a statistically
significant citalopram advantage and provided a Cohen’s d effect size of more than 1.

Conclusions

The present study finds a modest, non-significant benefit of citalopram over and above
that achieved by placebo for reducing parent-reported anxiety symptoms in children with ASD.
While the sample size is relatively large and the effect robust to different model assumptions,
the confidence intervals on the estimated effect were very wide and hence this finding still
leaves uncertainty about the potential of SSRIs to provide benefit for patients with ASD and
anxiety. Moreover, this study did not specifically enroll children with anxiety disorders.

Our findings indicate that there is a need for an authoritative trial of SSRIs for the
treatment of anxiety in children with ASD.

Clinical Significance

The present study finds a modest, non-significant benefit of citalopram over and above
that achieved by placebo for reducing parent-reported anxiety symptoms in children with ASD.
The original study showed that SSRIs can have significant adverse effects. Therefore, clinicians
should be cautious in their use of SSRIs for the treatment of anxiety in children with ASD. The present study does not alter current guidance suggesting that CBT-based psychological interventions should be the first line of treatment and SSRIs should be reserved for those who cannot make use of or do not respond to CBT, even when adapted or mediated by a parent/caregiver, or where levels of anxiety are so severe that a psychological approach cannot be implemented (National Collaborating Centre for Mental Health, 2013). Our findings highlight the need for an authoritative trial of SSRIs for the treatment of anxiety in people with ASD.
Acknowledgements

We thank Dr Kenneth Gadow for providing algorithms to calculate disorder cutoffs from the Child and Adolescent Symptoms Inventory (CASI-4).
1 References

3 for the assessment of treatment effects." American Journal of Mental Deficiency 89 (5):
4 485-491.

6 in patients with autism: temporal, regional, and demographic influences." Journal of


14 25.

15 Gabriele, S., R. Sacco, and A. M. Persico. 2014. "Blood serotonin levels in autism spectrum
16 disorder: a systematic review and meta-analysis." European Neuropsychopharmacology

19 preschool children with PDD and clinic and comparison samples." Journal of Autism &

22 Stony Brook, NY: Checkmate Plus.


health diagnoses in the autism population: a systematic review and meta-analysis." *The Lancet Psychiatry.*


tolerability in anxious and depressed youth at high risk for bipolar disorder: a

Stringer, D., R. Kent, J. Briskman, S. Lukito, T. Charman, G. Baird, C. Lord, A. Pickles, and E.
Simonoff. 2020. "Trajectories of emotional and behavioral problems from childhood to

rated anxiety symptoms in children with pervasive developmental disorders: frequency
and association with core autism symptoms and cognitive functioning." *Journal of

reuptake inhibitor monotherapy for anxiety disorders in children and adolescents with
autism spectrum disorder: A chart review." *Journal of Child & Adolescent
Psychopharmacology* 29 (9): 705-711.

Vasa, R. A., L. M. Carroll, A. A. Nozzolillo, R. Mahajan, M. O. Mazurek, A. E. Bennett, L. K. Wink,
and M. P. Bernal. 2014. "A systematic review of treatments for anxiety in youth with
autism spectrum disorders." *Journal of Autism & Developmental Disorders* 44 (12): 3215-
29.

randomized, placebo-controlled trial of citalopram for the treatment of major
1079-1083.


Williams, K., A. Brignell, M. Randall, N. Silove, and P. Hazell. 2013. "Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)." *Cochrane Database of Systematic Reviews* 8: CD004677.
1 Figure 1. Primary outcome (anxiety as measured with the CASI-4) for Baseline (Screener: placebo n=70, citalopram n=67) and Endpoint (Week 12: placebo n=58, citalopram n=56) – missing items imputed for those with 6 or fewer missing of the 20 items.

______________________________________________________________________________

2 Figure 2. Estimated effects of citalopram vs placebo on anxiety (as measured with the CASI-4), compared to hypothetical levels of change between baseline and endpoint: Log-transformed scores (left) and back transformed to raw scores (right).

[Figure description]

3 The figure shows the actual reduction in placebo and citalopram arms against predictions for no change (same as baseline), a reduction to 67% of baseline (just achieved by placebo - the ‘placebo effect’) and a further 33% treatment effect, not achieved by citalopram. This proportional effect on the raw score scale is shown on the right panel, the size of the expected treatment effect on the raw score increasing with the baseline level of symptoms and no effect expected for those with no symptoms. The red-dotted diagonal line indicates hypothetical continuity of the same level of anxiety.

______________________________________________________________________________

4 Figure 3. Venn diagram of anxiety disorders according to the diagnostic algorithm of the CASI-4
Figure 1. Primary outcome (anxiety as measured with the CASI-4) for Baseline (Screener: placebo n=70, citalopram n=67) and Endpoint (Week 12: placebo n=58, citalopram n=56) – missing items imputed for those with 6 or fewer missing of the 20 items.
Figure 2. Estimated effects of citalopram vs placebo on anxiety (as measured with the CASI-4), compared to hypothetical levels of change between baseline and endpoint: Log-transformed scores (left) and back transformed to raw scores (right).

[Figure description]

The figure shows the actual reduction in placebo and citalopram arms against predictions for no change (same as baseline), a reduction to 67% of baseline (just achieved by placebo - the ‘placebo effect’) and a further 33% treatment effect, not achieved by citalopram. This proportional effect on the raw score scale is shown on the right panel, the size of the expected treatment effect on the raw score increasing with the baseline level of symptoms and no effect expected for those with no symptoms. The red-dotted diagonal line indicates hypothetical continuity of the same level of anxiety.

546x397mm (144 x 144 DPI)
Figure 3. Venn diagram of anxiety disorders according to the diagnostic algorithm of the CASI-4

586x310mm (144 x 144 DPI)
Table 1. Characteristics of the Citalopram-treated and placebo groups

<table>
<thead>
<tr>
<th></th>
<th>Citalopram (n=73)</th>
<th>Placebo (n=76)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex, No. (%)</td>
<td>64 (87.7)</td>
<td>64 (84.2)</td>
</tr>
<tr>
<td>Age at consent, mean years (SD)</td>
<td>N=73 9.1 (3.2)</td>
<td>N=76 9.6 (3.1)</td>
</tr>
<tr>
<td>Non-verbal IQa</td>
<td>N=70 75.77 (28.08)</td>
<td>N=72 76.42 (29.05)</td>
</tr>
<tr>
<td>VABS Communication Age Equivalent, mean (SD)b</td>
<td>N=72 63.58 (36.99)</td>
<td>N=75 62.25 (40.69)</td>
</tr>
<tr>
<td>ADOS module completed, No. (%)a</td>
<td>N=71 1: 21 (28.77)</td>
<td>N=75 1: 20 (26.32)</td>
</tr>
<tr>
<td></td>
<td>2: 14 (19.18)</td>
<td>2: 19 (25.00)</td>
</tr>
<tr>
<td></td>
<td>3: 33 (45.21)</td>
<td>3: 32 (42.11)</td>
</tr>
<tr>
<td></td>
<td>4: 3 (4.11)</td>
<td>4: 4 (1.32)</td>
</tr>
<tr>
<td>Irritability, mean (SD)b</td>
<td>N=72 12.82 (8.44)</td>
<td>N=75 12.12 (8.24)</td>
</tr>
<tr>
<td>BMI, mean (SD)b</td>
<td>N=69 18.68 (4.74)</td>
<td>N=73 19.83 (5.50)</td>
</tr>
<tr>
<td>Autism severity (CGI-S)</td>
<td>Screener N=73 4.90 (0.78)</td>
<td>N=76 4.92 (0.74)</td>
</tr>
<tr>
<td></td>
<td>Week 12 N=55 4.44 (0.96)</td>
<td>N=61 4.49 (0.91)</td>
</tr>
</tbody>
</table>

a Measures of non-verbal IQ and the ADOS module were completed at one of the following time points (ranging from screener, baseline, week 2 or week 4)

b These measures were completed at the screening time point
Table 2. The number of participants experiencing at least one of the following adverse event types

<table>
<thead>
<tr>
<th>Type (n)</th>
<th>Citalopram</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuropsychiatric</td>
<td>43 (59%)</td>
<td>20 (26%)</td>
</tr>
<tr>
<td>Insomnia-related b</td>
<td>29 (40%)</td>
<td>19 (25%)</td>
</tr>
<tr>
<td>Non-CNS</td>
<td>30 (41%)</td>
<td>13 (17%)</td>
</tr>
</tbody>
</table>

a Participants experienced at least one of the following: increased energy level, disinhibited or impulsive behavior, decreased attention and concentration, hyperactivity, stereotypy

b Participants experienced at least one of the following: initial, midcycle or terminal insomnia

c Participants experienced at least one of the following: diarrhea, vomiting or nausea, dry skin or pruritus
### Supplementary Table 1. 20 anxiety items used from the CASI

<table>
<thead>
<tr>
<th>Item no.</th>
<th>Item description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D47</td>
<td>Is over concerned about abilities in school, athletic, work or social activities</td>
</tr>
<tr>
<td>D48</td>
<td>Has difficulty controlling worries</td>
</tr>
<tr>
<td>D49</td>
<td>Acts restless or edgy</td>
</tr>
<tr>
<td>D51</td>
<td>Is extremely tense or unable to relax</td>
</tr>
<tr>
<td>D52</td>
<td>Has difficulty falling asleep or staying asleep</td>
</tr>
<tr>
<td>E53</td>
<td>Is overly fearful of (or tries to avoid) specific objects or situations (animals, heights, storms, going places alone, being “trapped”, etc.)</td>
</tr>
<tr>
<td>E54</td>
<td>Complains about heart pounding, shortness of breath, feeling dizzy, trembling, or fear of dying</td>
</tr>
<tr>
<td>E55</td>
<td>Cannot get distressing thoughts out of mind</td>
</tr>
<tr>
<td>E61</td>
<td>Complains about physical problems (headaches, upset stomach etc.) for which there is no apparent</td>
</tr>
<tr>
<td>E62</td>
<td>Worries about physical health</td>
</tr>
<tr>
<td>F63</td>
<td>Is more anxious in social situations than most other children</td>
</tr>
<tr>
<td>F64</td>
<td>Is excessively shy with peers</td>
</tr>
<tr>
<td>G65</td>
<td>Gets very upset when he/she expects to be separated from home or parents</td>
</tr>
<tr>
<td>G66</td>
<td>Worries that parents will be hurt or leave home and not come back</td>
</tr>
<tr>
<td>G67</td>
<td>Worries that some disaster (getting lost, kidnapped, etc.) will separate him/her from parents</td>
</tr>
<tr>
<td>G68</td>
<td>Tries to avoid going to school in order to stay home with parent</td>
</tr>
<tr>
<td>G69</td>
<td>Worries about being left at home alone or with a sitter</td>
</tr>
<tr>
<td>G70</td>
<td>Afraid to go to sleep unless near parent</td>
</tr>
<tr>
<td>G71</td>
<td>Has nightmares about being separated from parent</td>
</tr>
<tr>
<td>G72</td>
<td>Complains about feeling sick when he/she expects to be separated from home or parents</td>
</tr>
</tbody>
</table>
Supplementary Table 2. Anxiety scores after imputation for those with 6 or less items missing from the 20 CASI anxiety items

<table>
<thead>
<tr>
<th>Screener</th>
<th>Week 12</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Citalopram (n=67)</td>
</tr>
<tr>
<td>Total anxiety score, mean (SD)(^a)</td>
<td>12.96 (8.63)</td>
</tr>
</tbody>
</table>